Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award

This article was originally published in The Pink Sheet Daily

Executive Summary

A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.

You may also be interested in...



Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit

In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.

States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases

First the federal government came knocking at their doors and then state attorneys general followed with claims of health care fraud. Now drug makers are dealing with another nemesis: states that file individual suits instead of joining multistate settlements.

States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases

First the federal government came knocking at their doors and then state attorneys general followed with claims of health care fraud. Now drug makers are dealing with another nemesis: states that file individual suits instead of joining multistate settlements.

Related Content

Topics

UsernamePublicRestriction

Register

PS071310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel